AstraZeneca PLC
LSE:AZN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9 354.2809
13 276
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
AstraZeneca PLC
AstraZeneca PLC
Revenue
AstraZeneca PLC
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AstraZeneca PLC
LSE:AZN
|
Revenue
$49.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Revenue
£31.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Revenue
$5.6m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Revenue
$1.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
4%
|
CAGR 10-Years
0%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Revenue
$3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Revenue
£761.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
AstraZeneca PLC
Revenue Breakdown
Breakdown by Geography
AstraZeneca PLC
|
Total Revenue:
45.8B
USD
|
|
The Americas:
20.8B
USD
|
|
Asia, Africa And Australasia:
11.9B
USD
|
|
Europe:
9.7B
USD
|
|
China:
5.9B
USD
|
|
Japan:
3.6B
USD
|
|
Uk:
3.4B
USD
|
|
Other, Europe:
3.1B
USD
|
|
Sweden:
1.7B
USD
|
|
France:
1.2B
USD
|
|
Canada:
967m
USD
|
|
Spain:
847m
USD
|
|
Italy:
813m
USD
|
|
Australia:
390m
USD
|
Breakdown by Segments
AstraZeneca PLC
|
Total Revenue:
45.8B
USD
|
|
Total Oncology:
17.1B
USD
|
|
Cvrm:
10.6B
USD
|
|
Rare Disease:
7.8B
USD
|
|
Farxiga:
6B
USD
|
|
Tagrisso:
5.8B
USD
|
|
Imfinzi:
4.2B
USD
|
|
Soliris:
3.1B
USD
|
|
Ultomiris:
3B
USD
|
|
Lynparza:
2.8B
USD
|
|
Calquence:
2.5B
USD
|
|
Symbicort:
2.4B
USD
|
|
Fasenra:
1.6B
USD
|
|
Brilinta:
1.3B
USD
|
|
Total Other Medicines:
1.2B
USD
|
|
Strensiq:
1.2B
USD
|
|
Crestor:
1.1B
USD
|
|
Enhertu:
1B
USD
|
|
Zoladex:
952m
USD
|
|
Nexium:
945m
USD
|
|
Pulmicort:
713m
USD
|
|
Breztri:
677m
USD
|
|
Seloken/Toprol-Xl:
640m
USD
|
|
Synagis:
546m
USD
|
|
Lokelma:
412m
USD
|
|
Koselugo:
331m
USD
|
|
Faslodex:
297m
USD
|
|
Saphnelo:
280m
USD
|
|
Roxadustat:
271m
USD
|
|
Other, Others:
231m
USD
|
|
Onglyza:
227m
USD
|
|
Oncology, Others:
224m
USD
|
|
Flumist:
216m
USD
|
|
Andexxa:
182m
USD
|
|
Kanuma:
171m
USD
|
|
Bydureon:
163m
USD
|
|
Bevespi:
58m
USD
|
|
Daliresp/Daxas:
54m
USD
|
|
Vaxzevria:
12m
USD
|
AstraZeneca PLC
Glance View
AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.
See Also
What is AstraZeneca PLC's Revenue?
Revenue
49.1B
USD
Based on the financial report for Jun 30, 2024, AstraZeneca PLC's Revenue amounts to 49.1B USD.
What is AstraZeneca PLC's Revenue growth rate?
Revenue CAGR 10Y
6%
Over the last year, the Revenue growth was 10%. The average annual Revenue growth rates for AstraZeneca PLC have been 18% over the past three years , 16% over the past five years , and 6% over the past ten years .
You don't have any saved screeners yet
